Broadening inclusion of vulnerable populations in HIV vaccine trials.

Abstract

The urgent need for a preventive HIV vaccine, as well as the complexities of its development, calls for timely and reinforced efforts to ensure vaccine licensure for use in a broad range of at-risk populations from the outset. Such an integrated strategy to HIV vaccine development should include infants of HIV-infected women, adolescents and injection drug users. A safe and effective HIV vaccine licensed for use in these populations, in addition to sexually active adults, would probably have the most timely and profound impact on the HIV/AIDS pandemic. Advanced clinical development of HIV vaccines in these vulnerable populations imposes particular scientific, operational and ethical challenges. Recent developments, including the early termination of a Phase IIb trial, present additional previously unanticipated challenges.

• Authors: Chuen-Yen Lau, Massimo Cardinali, Paul A Sato, Alan Fix, Jorge Flores
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 7 Issue 2 Pg. 259-68 (Mar 2008) ISSN: 1744-8395 [Electronic] England
• PMID: 18324894 (Publication Type: Journal Article, Review)

Chemical References

• AIDS Vaccines

Topics

• AIDS Vaccines (administration & dosage, adverse effects, therapeutic use)
• Adolescent
• Adult
• Animals
• Clinical Trials as Topic (legislation & jurisprudence)
• Female
• HIV Infections (prevention & control, transmission, virology)
• HIV-1 (immunology)
• Humans
• Infant
• Infant, Newborn
• Infectious Disease Transmission, Vertical
• Pregnancy
• Pregnancy Complications, Infectious (prevention & control, virology)
• Risk Factors
• Substance Abuse, Intravenous (complications)
• Vulnerable Populations